Business Context and Reporting Period
Bone Biologics Corporation, a Delaware corporation, filed this Form 8-K on April 8, 2016, reporting events occurring on April 7, 2016. The filing discloses the entry into a material definitive consulting agreement.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the new consulting agreement:
- Up-front Retainer: $100,000
- Monthly Fee: $33,333.33
- Total Contract Value (3 months): $200,000
Material Changes
The Company entered into a Consulting Agreement with AFH Holdings & Advisory, LLC ("AFH") effective April 5, 2016. The agreement covers an initial term of three months. Amir Heshmatpour, the controlling party of AFH, is identified as an affiliate and board observer of the Company.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies are detailed beyond the disclosure of the related-party nature of the agreement with an affiliate.
Investor Verification Checklist
- Verify the total cash outflow impact of the $200,000 consulting fee against current liquidity.
- Confirm the specific scope of services to be provided by AFH Holdings & Advisory, LLC.
- Review the relationship between Amir Heshmatpour and the Company's board to assess potential conflicts of interest.
- Check subsequent filings for any extensions or modifications to the three-month term.